The industry must now address critical challenges, including pricing negotiations, payer coverage limitations, supply constraints and the preservation of muscle mass during weight loss, with solutions emerging through novel mechanisms targeting amylin, cannabinoid receptors and activin pathways. 1 Sales Projections Far Outpace Other Drugs on Clarivates 2026 Watch List An FDA decision on orforglipron is expected by March 2026, with Clarivate projecting retatrutide will be ready for launch in 2028
In an April news release, Empower said it employs more than 1,200 people
The side effects of Wegovy are often non-serious, with 99.5% of gastrointestinal events categorised as such, and 98.1% were mild to moderate in severity
Popa T, Hubsch C, James P, Richard A, Russo M, Pradeep S, et al
The point is, it's not in your head
Miglior, F